News articles about Trinity Biotech (NASDAQ:TRIB) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trinity Biotech earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.8112880226835 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Trinity Biotech (NASDAQ TRIB) traded down $0.02 on Friday, reaching $4.93. 40,352 shares of the company’s stock were exchanged, compared to its average volume of 59,408. The company has a quick ratio of 3.77, a current ratio of 5.16 and a debt-to-equity ratio of 0.90. Trinity Biotech has a 12-month low of $4.22 and a 12-month high of $7.27. The firm has a market cap of $117.08, a price-to-earnings ratio of 81.17 and a beta of 1.41.
Trinity Biotech (NASDAQ:TRIB) last released its earnings results on Thursday, October 26th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Trinity Biotech had a negative net margin of 100.00% and a positive return on equity of 5.87%. The firm had revenue of $25.60 million during the quarter, compared to analyst estimates of $25.52 million. equities analysts forecast that Trinity Biotech will post 0.06 earnings per share for the current fiscal year.
Separately, Zacks Investment Research lowered shares of Trinity Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, September 20th.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Trinity Biotech (TRIB) Stock Price” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/10/trinity-biotech-plc-trib-receiving-somewhat-positive-news-coverage-accern-reports.html.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech plc and related companies with MarketBeat.com's FREE daily email newsletter.